Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September
Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September
To learn more, please visit and follow us on LinkedIn.NEW YORK and WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of September:
Dianthus Therapeutics，Inc.（納斯達克：DNTH）是一家臨床階段的生物技術公司，致力於推進下一代抗體互補治療劑以治療嚴重自身免疫性疾病。今天，公司宣佈將於9月舉行以下醫療健康投資者會議上的演講及公司全貌介紹。
- Baird 2024 Global Healthcare Conference on September 11 at 2:00 p.m. ET in New York City
- Cantor 2024 Global Healthcare Conference on September 17 at 10:55 a.m. ET in New York City
-
Stifel 2024 Virtual Immunology and Inflammation Summit on September 18 at 10:30 a.m. ET via Zoom
- 9月11日下午2點在紐約舉辦的2024 Baird 全球醫療健康大會
- 9月17日上午10點55分在紐約舉辦的2024 Cantor 全球醫療健康大會
- 9月18日上午10點30分通過Zoom參加的2024 Stifel 虛擬免疫學和炎症峯會
Live webcasts of the Company's presentations at the Cantor and Stifel conferences may be accessed under "News and Events" in the Investors section of the Dianthus Therapeutics website.
可以在Dianthus Therapeutics網站的投資者部分的「新聞與事件」中獲取公司在Cantor和Stifel會議上的演講的現場網絡直播。
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
關於Dianthus Therapeutics
Dianthus Therapeutics是一家臨床階段的生物技術公司，致力於設計和提供具有改進選擇性和效力的新型頭孢單克隆抗體。總部位於紐約市和沃爾瑟姆，迪安斯由一支經驗豐富的生物技術和製藥行業高管團隊組成，他們領導着下一代抗體互補治療的開發，旨在爲患有嚴重自身免疫和炎症性疾病的人群提供革命性的藥物。
To learn more, please visit and follow us on LinkedIn.
要了解更多信息，請訪問和我們一起LinkedIn.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
聯繫
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
譯文內容由第三人軟體翻譯。